Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
mRNA Therapeutics CDMO Market Poised To Hit $8.26 Billion By 2030 With A 11.7% CAGR
The mrna therapeutics cdmo market size has experienced rapid growth in recent years. This market is expected to expand from $4.74 billion in 2025 to $5.31 billion in 2026, with a compound annual growth rate (CAGR) of 12.0%. The historical growth can be ascribed to several factors, including the limited availability of specialized mrna cdmo services, a reliance on in-house pharmaceutical manufacturing, an increase in infectious disease outbreaks, the adoption of early-stage analytical testing, and the expansion of academic and research collaborations.
The mrna therapeutics cdmo market size is poised for significant expansion in the coming years. This market is projected to reach $8.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. Key factors driving this growth during the forecast period include increasing investment in mRNA therapeutics pipelines, advancements in plasmid DNA and mRNA synthesis technologies, the expansion of cancer immunotherapy and protein replacement therapies, a heightened demand for fill-finish services, and the proliferation of partnerships between biopharmaceutical companies and CDMOs. Significant trends anticipated in the same period involve a growing need for outsourced mRNA development and manufacturing, a sharpened focus on lipid nanoparticle (LNP) formulation technologies, the broadening of viral vaccine and cancer immunotherapy pipelines, improved regulatory compliance and quality assurance protocols, and the wider acceptance of analytical and bioanalytical laboratory services.
Get A Free Sample Report With In-Depth Market Insights:
mRNA Therapeutics CDMO Market Growth Catalysts And Demand Drivers
The increasing prevalence of chronic and infectious diseases is anticipated to propel the expansion of the mRNA therapeutics CDMO market in the future. These conditions include enduring health issues like diabetes, cardiovascular disorders, and asthma, alongside illnesses stemming from harmful microorganisms such as viruses, bacteria, and parasites, capable of direct or indirect transmission between individuals. The rise in chronic and infectious diseases is linked to an aging global population, which is more prone to both persistent health conditions and infections. mRNA therapeutics CDMO plays a role in tackling these diseases by offering comprehensive development and production services, speeding up the delivery of precise, customized mRNA treatments to patients. For instance, in October 2024, the World Health Organization, a Switzerland-based international public health organization, reported that new tuberculosis diagnoses reached approximately 8.2 million individuals in 2023, an increase from about 7.5 million in 2022, underscoring the worsening global impact of infectious diseases. Consequently, the expanding challenge posed by chronic and infectious diseases is a primary catalyst for the growth of the mRNA therapeutics CDMO market.
mRNA Therapeutics CDMO Market Segments: Where Is Growth Concentrated?
The mrna therapeutics cdmo market covered in this report is segmented –
1) By Type Of Service: Development Services, Manufacturing Services, Laboratory Services
2) By Indication: Infectious Diseases, Metabolic And Genetic Diseases, Cardiovascular And Cerebrovascular Diseases
3) By Application: Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies
4) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations
Subsegments:
1) By Development Services: Process Development, Analytical Method Development, Formulation Development, Regulatory Support
2) By Manufacturing Services: Plasmid DNA Manufacturing, mRNA Synthesis, Lipid Nanoparticle (LNP) Formulation, Fill-Finish Services
3) By Laboratory Services: Quality Control Testing, Stability Testing, Bioanalytical Testing, Preclinical Testing
mRNA Therapeutics CDMO Market Trends Shaping Long-Term Demand
Major companies within the mRNA therapeutics CDMO market are concentrating on developing pioneering solutions, such as in situ nanomedicine vaccines, to improve the effectiveness and precision of mRNA-based vaccines through focused immune stimulation. An in situ nanomedicine vaccine represents an advanced mRNA-based therapeutic designed to generate nanomedicines inside the patient’s body, enabling targeted delivery and personalized immune activation via engineered transgene expression. For example, in January 2025, Esphera SynBio Inc., a biotechnology company based in Canada, launched a new project with the backing of the CQDM Quantum Leap program. This undertaking aims to enhance first-generation lipid nanoparticle or messenger RNA (LNP/mRNA) vaccines by integrating proprietary transgene designs that facilitate the in vivo production of immunostimulatory nanomedicines. This methodology allows for exact antigen delivery and customized immune responses, positioning the technology as a potential breakthrough in vaccine innovation.
mRNA Therapeutics CDMO Market Key Participants And Competitive Landscape
Major companies operating in the mrna therapeutics cdmo market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG.
View The Full mRNA Therapeutics CDMO Market Report:
mRNA Therapeutics CDMO Market Top Region By Revenue And Market Share
North America was the largest region in the mRNA therapeutics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
